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Abstract
Objectives: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic
drug (DMARD)-free remission in patients with rheumatoid arthritis (RA).
Methods: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients
participated in a disease activity score (DAS) < 1.6 steered trial aimed at DMARD-free remission. Initial treatment
comprised methotrexate with high-dose prednisone (60 mg/day) and a possibility to start biologicals after 4 months. In
the same period and hospital, 124 patients were treated according to routine care, comprising DAS < 2.4 steered
treatment. Percentages of DMARD-free remission (absence of synovitis for ≥ 1 year after DMARD cessation), late flares
(recurrence of clinical synovitis ≥ 1 year after DMARD cessation), and DMARD-free sustained remission (DMARD-free
remission sustained during complete follow-up) were compared between both treatment strategies.
Results: Patients receiving intensive treatment were younger and more often ACPA-positive. On a group level, there
was no significant association between intensive treatment and DMARD-free remission (35% vs 29%, corrected hazard
ratio (HR) 1.4, 95%CI 0.9–2.2), nor in ACPA-negative RA (49% versus 44%). In ACPA-positive RA intensive treatment
resulted in more DMARD-free remission (25% vs 6%, corrected HR 4.9, 95%CI 1.4–17). Intensive treatment was associated
with more late flares (20% versus 8%, HR 2.3, 95%CI 0.6–8.3). Subsequently, there was no difference in DMARD-free
sustained remission on a group level (28% versus 27%), nor in the ACPA-negative (43% versus 42%) or ACPA-positive
stratum (17% versus 6%, corrected HR 3.1, 95%CI 0.9–11).
Conclusions: Intensive treatment did not result in more DMARD-free sustained remission, compared to routine up-to-
date care. The data showed a tendency towards an effect of intensive treatment in ACPA-positive RA; this needs
further investigation.
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Introduction
Over the last decades, treatment of rheumatoid arthritis
(RA) has changed dramatically. Treatment targets have
shifted from mere relief of symptoms towards treat-to-tar-
get therapy aimed at remission and prevention of struc-
tural joint damage [1–3]. The recent European League
Against Rheumatism (EULAR) recommendations for
the management of RA state that treatment should be
aimed at sustained remission or low disease activity,
defined according to Boolean or index-based defini-
tions, which correspond with the absence of radiologic
damage [2, 4]. These treatment aims can be achieved
while patients are still on disease-modifying antirheu-
matic drugs (DMARDs).
Although RA is considered a chronic disease, there is
growing evidence that a proportion of patients can achieve
DMARD-free remission with reported percentages ran-
ging between 3.6 and 23% [5–12]. To note, varying defini-
tions of DMARD-free remission were used in these
studies. DMARD-free sustained remission, which has been
defined as the sustained absence of arthritis after cessation
of DMARDs, may be interpreted as the closest proxy to
cure of RA, especially as it also corresponds with a
patient-perceived state of remission in terms of nor-
malized levels of physical functioning, pain, fatigue, and
stiffness [13, 14]. Although studies have shown it is an
achievable goal in part of RA patients, EULAR re-
commendations are cautious with regard to tapering and
stopping DMARDs. The main reason for this being the
lack of evidence about safely stopping DMARD therapy
and the risk of flares [2, 15–17].
The presence of RA-related autoantibodies asso-
ciates with a decreased risk of DMARD-free sustained
remission [10, 13], but biologic mechanisms mediating
resolution of RA chronicity are mostly unknown [5].
Studies have shown that with better treatment options
and the introduction of disease activity score (DAS)-steered
treatment, DMARD-free remission has become a more
achievable outcome [13]. However, it is unclear if
current DAS-steered treatment, starting with metho-
trexate (MTX), results in an optimum chance for
achieving this outcome, or whether a more intensive
DAS-steered treatment regimen can result in an even
higher proportion of patients achieving and sustaining
DMARD-free remission.
Therefore, this study assessed if treatment strategy
impacts the chance of disease resolution. We compared
the prevalence of DMARD-free remission, as well as
DMARD-free sustained remission between patients
treated according to an intensive DAS-steered treatment
strategy as applied in the setting of a clinical trial (the
IMPROVED study) [18] and patients treated according to
routine care, in line with EULAR recommendations [2].
All studied patients were treated in the same center by the
same rheumatologists. In short, trial patients were treated
DAS (< 1.6) steered and started with high-dose prednisone
next to MTX, whereas routine care consisted of initial
MTX- and DAS (< 2.4) steered treatment.
Methods
Patients
All patients who were newly diagnosed with RA (accor-
ding to the 2010 criteria) between March 2007 and
September 2010 in the Leiden University Medical Center
and who were included in the Leiden Early Arthritis
Clinic (EAC) [19] were selected for this study (n = 313,
Fig. 1). The EAC is a prospective, population-based
inception cohort that includes patients with clinically
confirmed arthritis and a symptom duration < 2 years
[19]. Besides regular visits with their rheumatologist,
patients had scheduled study visits at least once a year,
including questionnaires, physical examination, and
blood samples. All patients were treated by the same
team of rheumatologists in the same center, but accor-
ding to different treatment strategies; either according to
an intensive DAS-steered treatment regimen within the
IMPROVED study [18] or according to up-to-date rou-
tine care (see below for more details). In order to study
a homogenous group of patients, those who did not
fulfill the inclusion criteria of the IMPROVED study (see
below) or were not started on DMARD therapy were
excluded (n = 34) (Fig. 1). Thus, a total of 279 patients
were studied. In principle, all patients could have been
included in the IMPROVED study. Nevertheless, only
155 patients were included. Reasons why 124 patients
were not included were not routinely documented, but
could either be patient related (for example, patient
did not want to participate), rheumatologist related
(rheumatologist did not ask patient to participate), or both.
Intensive treatment
The IMPROVED study is a multicenter randomized
single-blinded clinical trial that recruited 610 patients
between March 2007 and September 2010 [18]. For
inclusion, patients had to be ≥ 18 years, have a diagnosis
of early RA or UA, a DAS ≥ 1.6, and no prior use of
DMARDs. In contrast to routine care, all patients were
started on high-dose prednisone 60 mg/day which was
tapered to 7.5 mg/day in 7 weeks and MTX, starting at
7.5 mg per week and escalated to 25mg/week. If patients
were in early remission (DAS < 1.6) after 4 months,
prednisone was tapered to stop and if patients were still
in remission after 8-months MTX was tapered and
stopped as well over the next 4 months. If patients were
not in remission after 4 months, they were randomized
either to adding hydroxychloroquine and sulphasalazine
to MTX and prednisone or to switching to MTX plus
adalimumab. Patients had 4 monthly visits, and medication
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was tapered or stopped in case of a DAS < 1.6 and
restarted, switched, or increased in case of a DAS ≥ 1.6.
Primary outcomes were DAS-remission and drug-free
remission based on a DAS < 1.6. The study has previously
been described [18, 20] and was approved by the Medical
Ethical Committee. All patients provided written informed
consent. For the present study, only patients included in
the Leiden University Medical Center and who fulfilled
the 2010 criteria for RA were studied (n = 155). Thus,
this concerned a subgroup of patients from the total
IMPROVED study (Fig. 1). The follow-up duration of
the IMPROVED study was 5 years; thereafter, follow-up
of all patients continued within the EAC cohort and
patients were treated routinely.
Routine care
In line with EULAR recommendations [2] and local guide-
lines, routine care comprised DAS (< 2.4) steered treatment,
where treatment was initially started with MTX. In case of a
DAS < 2.4, treatment was generally tapered and eventually
stopped, whereas in case of a DAS ≥ 2.4, treatment was
intensified. After the failure of > 2 conventional DMARDs,
biologics were allowed. Thus, similar to patients receiving
intensive treatment, routine care was DAS steered and
tapering and stopping of DMARDs was routine; how-
ever, the treatment target differed (DAS < 1.6 versus
DAS < 2.4). Of all patients receiving routine care, 67
(54%) received initial combination therapy of MTX with
corticosteroids (either oral prednisone (median starting
dose 10mg/day (interquartile range 7.5, 17.5) or intramus-
cular as Methylprednisolone with doses ranging between
80 and 120mg). During complete follow-up, 17 patients
(14%) were treated with biologicals, but none were
initiated within the first year of follow-up. The course of
the DAS score in patients receiving routine care is
depicted in Additional file 1: Figure S1.
Fig. 1 Flowchart of patient selection. Figure depicting patient selection for the current study. EAC, early arthritis clinic; RA, rheumatoid arthritis;
DAS, disease activity score; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate. Patients in the regular treatment group that did
not fulfill the inclusion criteria of the IMPROVED study were excluded for reasons of comparability. *For patients who participated in the
IMPROVED study, follow-up after conclusion of the study (after 5 years) continued in the EAC cohort according to routine care
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Ethical approval. The study was approved by the Medical
Ethical Committee of the LUMC (“Commissie Medische
Ethiek LUMC”). All patients provided written in-
formed consent.
Outcome
Three outcomes were studied. The first was DMARD-free
remission, defined as the absence of clinical synovitis for
≥ 1 year after DMARD cessation; hence, patients with
early recurrence of synovitis after DMARD stop were not
included in this group. The second outcome was the oc-
currence of late flares, defined as recurrence of clinical
synovitis after having achieved DMARD-free remission:
thus, a recurrence of clinical synovitis more than 1 year
after DMARD cessation. So, if patients had a recurrence
of clinical synovitis within 1 year after DMARD cessation,
this was not considered a late flare; then, follow-up con-
tinued and patients were considered as not being in
DMARD-free remission. Thirdly, DMARD-free sustained
remission, defined as the absence of clinical synovitis for
> 1 year after DMARD cessation and for the remainder of
the follow-up, was studied. Thus, these were the patients
in DMARD-free remission minus those with a late flare.
Importantly, these outcomes were different from the out-
comes studied in the IMPROVED study, which were sus-
tained drug-free remission, defined as a period of
drug-free remission based on a DAS < 1.6 for ≥ 1 year,
regardless of a need to restart DMARD therapy after this
period, radiographic joint damage, and functional dis-
ability. Radiographic damage was not studied here as,
based on previous studies including the IMPROVED
study, we expected little clinically relevant joint damage
[18, 21]. All medical records were assessed on these out-
comes between March and May 2017. If patients were in
DMARD-free (sustained) remission, the date of remission
was the date 1 year after cessation of DMARDs. For
patients not in DMARD-free (sustained) remission, the
censoring date was either the date of going through the
medical records, or an earlier date in case patients was lost
to follow-up or had died.
Statistics
Baseline characteristics were compared using Students’
t tests, chi-square tests, and Mann-Whitney U tests, as
appropriate. Kaplan-Meier curves were used to depict
the occurrence of DMARD-free (sustained) remission
and late flares over time. Univariable and multivariable
Cox-regression proportional hazards models were used
to study associations between treatment strategy and
achieving DMARD-free (sustained) remission or late
flares. Multivariable models were adjusted for baseline
differences. An analysis corrected for the propensity
score was performed as a sensitivity analysis to reduce
possible bias caused by confounding by indication
(Additional file 1: Supplementary methods). Because a
baseline difference in anticitrullinated protein antibody
(ACPA) positivity was observed and ACPA positivity is
associated with a lower risk of DMARD-free remission
[10, 13], analyses were stratified by ACPA status (EliA
CCP2, Phadia, Nieuwegein, the Netherlands, positive if
≥ 7 U/mL, determined at baseline). Analyses were per-
formed in SPSS version 24.0. P values < 0.05 were consi-
dered statistically significant.
Results
Baseline characteristics
Baseline characteristics are depicted in Table 1. Most
characteristics were similar for both treatment strategies,
but patients receiving intensive treatment were younger
(mean of 53 versus 61 years, p < 0.001) and more often
auto-antibody positive (59% versus 40% for ACPA
positivity, p = 0.003 and 65% versus 48% for rheumatoid
factor (RF) positivity, p = 0.005). The median follow-up
duration of all patients was 7.8 years (IQR 6.8–8.7 years)
and was similar for both treatment strategies (median
7.8 years in both groups).
Table 1 Baseline characteristics
RA patients receiving intensified treatment (n = 155) RA patients receiving routine care (n = 124) p value
Age, mean (SD) 53 (14) 61 (15) < 0.001
Female gender, n (%) 106 (68) 80 (65) 0.50
Symptom duration < 12 weeks, n (%) 60 (39) 47 (38) 0.81
66-SJC, median (IQR) 6 (3–11) 7 (3–11) 0.79
68-TJC, median (IQR) 12 (7–20) 12 (6–19) 0.32
ESR, median (IQR) 25 (11–41) 31 (14–46) 0.25
DAS44, median (IQR) 3.1 (2.6–3.8) 3.0 (2.5–3.7) 0.30
ACPA-positive, n (%)* 92 (59) 50 (40) 0.003
RF-positive, n (%)* 101 (65) 60 (48) 0.005
Table depicting baseline characteristics of all patients included in the present study. Missings were as follows: ACPA (2), TJC (9), SJC (8), ESR (1), DAS44 (11).
*ACPA-positive if ≥ 7 U/mL and IgM rheumatoid factor (RF)-positive if ≥ 3.5 IU/mL. RA rheumatoid arthritis, SD standard deviation, SJC swollen joint count, TJC
tender joint count, IQR interquartile range, ESR erythrocyte sedimentation rate, ACPA anticitrullinated protein antibody, RF rheumatoid factor
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DMARD-free remission
DMARD-free remission was achieved by 35% (54/155)
of patients receiving intensive treatment after a median
of 3.0 years and by 29% (36/124) of patients receiving
routine care after a median of 4.1 years (Fig. 2a). Baseline
characteristics of these 54 and 36 patients are shown in
Additional file 1: Table S1 and reveal that patients
achieving DMARD-free remission in the intensive
treatment arm were older and more often auto-anti-
body positive compared to routine care (thus, similar to
the baseline characteristics on group level). An inten-
sive treatment strategy was not significantly associated
with a higher chance on achieving DMARD-free remis-
sion (hazard ratio (HR) 1.2, 95%CI 0.8–1.8). Also, after
correction for baseline differences (age, ACPA, and RF),
no significant association was observed (HR 1.4, 95%CI
0.9–2.2).
Because of the baseline difference in ACPA positivity
between the groups and because we hypothesized that
an impact of treatment strategy on DMARD-free re-
mission might be different in ACPA-positive and
ACPA-negative RA patients, analyses were stratified by
ACPA status. Within both strata, patient characteristics
were similar, except for a younger age in patients re-
ceiving intensive treatment in both strata (Table 2).
Within ACPA-positive patients, intensive treatment
was associated with a higher chance on achieving
DMARD-free remission (25% versus 6%, HR corrected
for age 4.9, 95%CI 1.4–16.9, Fig. 2b). Within ACPA-
negative RA patients, the percentage of patients achieving
DMARD-free remission was similar for both treatment
strategies (49% versus 44% in routine care, Fig. 2c).
No Cox-regression analysis was performed within
ACPA-negative patients as the assumption of propor-
tional hazards was not met (Fig. 2c).
Late flares
A total of 90 patients achieved DMARD-free remission,
and these patients were at risk for having a late flare. In
these patients, the median follow-up after having
achieved DMARD-free remission was 4.7 (95%CI 2.2–
6.4) years. A late flare was observed in 20% (11/54) of
patients receiving intensive treatment and in 8% (3/36)
of patients in the routine care group (HR 2.3, 95%CI
0.6–8.3, Fig. 3a–c). No multivariable analyses or strati-
fied analyses were performed, because of the small num-
ber of events. Of the 14 patients in whom a late flare
occurred, 8 presented with polyarthritis at the time of
flare, 4 with oligoarthritis, and 2 with monoarthritis. The
presence of ACPA and/or RF was associated with the
occurrence of a late flare (Additional file 1: Table S2;
HR 1.23 (1.02–1.50) for ACPA and 6.34 (1.77–22.79)
for RF positivity).
DMARD-free sustained remission
Patients with late flares were not included in the group
of RA patients that achieved DMARD-free sustained
remission. DMARD-free remission that sustained until the
end of follow-up was observed in 28% (43/155) of patients
receiving intensive treatment and in 27% (33/124) of
patients receiving routine care. Also here, the assumption
of proportional hazards was not met; thus, Cox-regression
Fig. 2 Kaplan-Meier curves depicting the percentage of patients
achieving DMARD-free remission by treatment strategy. Figure
depicting comparisons of DMARD-free remission by treatment
strategy in all included patients (a) and stratified by ACPA status
(b, c). DMARD, disease-modifying antirheumatic drug; HR, hazard
ratio; ACPA, anticitrullinated protein antibodies; IT, intensive
treatment; RC, routine care
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analyses were not performed. However, these data showed
no difference between the groups (Fig. 4a).
Within the ACPA-positive stratum, DMARD-free sus-
tained remission was achieved by 17% (16/92) of patients
receiving intensive treatment and by 6% (3/50) of
patients receiving routine care (Fig. 4b). This difference
was not statistically significant (HR corrected for age 3.1,
95%CI 0.9–11.0). Within the ACPA-negative stratum,
the percentage of patients achieving DMARD-free sus-
tained remission was similar (43% versus 42% in routine
care, Fig. 4c).
In order to further decrease, the chance on confound-
ing by indication, analyses on DMARD-free sustained
remission were repeated and corrected for the propen-
sity score. This revealed similar results, namely that
patients receiving intensive treatment had a HR of 1.3
(95%CI 0.8, 2.1) on achieving DMARD-free sustained
remission.
Discussion
This study compared a treatment strategy that is inten-
sive in treatment target and in the medications used
with an up-to-date regular treatment strategy, with
DMARD-free sustained remission as long-term outcome.
An intensive treatment strategy was not associated with a
higher prevalence of DMARD-free sustained remission,
nor after correction for baseline differences, nor after
correction for a propensity score. Stratification for
ACPA revealed that ACPA-positive RA patients in the
intensive treatment group achieved DMARD-free re-
mission more often but also had a higher rate of late
flares. Therefore, our current results do not provide evi-
dence for long-term benefits of an intensive DAS-steered
treatment regimen with regard to achieving DMARD-free
sustained remission.
While a randomized trial would have been the best
method to compare the two treatment strategies because
of the element of randomization, the present study does
have some important advantages. The first is the long-
term follow-up duration. Trials often have a limited
follow-up duration which hampers the evaluation of long-
term outcomes. In the IMPROVED trial, the follow-up
was restricted to 5 years. The median follow-up in this
study was almost 8 years as patients were followed-up in
the EAC cohort after conclusion of the trial, and some
patients had a follow-up of > 10 years.
A second strength of our study is that the whole
source population of RA patients newly classified with
RA in a time-period in one center was studied. Trials
include sets of patients with certain characteristics,
hampering extrapolation to the general population of
RA-patients. Furthermore, the IMPROVED trial did not
include a regular treatment arm [18]. Comparing RA
patients treated in this trial with RA patients treated by
the same team of rheumatologists according to routine
care allowed to evaluate whether an intensive trial regi-
men is favorable for the long-term outcome studied. As
mentioned previously, an important issue is why almost
half of the recent-onset RA patients that met the inclu-
sion criteria of the IMPROVED study did not partici-
pate. Reasons for not participating were not routinely
documented and may be related to willingness of the
patient or preference of the rheumatologist. Relatively
few differences in patient characteristics were observed
between the two groups. The most important difference
was the prevalence of ACPA; possibly rheumatologists
or patients themselves were less motivated in case of
ACPA negativity. Since ACPA has been associated with
a lower hazard on achieving DMARD-free remission
[10, 13], analyses were repeated after stratification by
ACPA status to prevent bias. In the whole group,
Table 2 Baseline characteristics stratified for the presence of ACPA
ACPA-positive p
value
ACPA-negative p
valueRA patients receiving
intensified treatment (n = 92)
RA patients receiving
routine care (n = 50)
RA patients receiving
intensified treatment (n = 63)
RA patients receiving
routine care (n = 72)
Age, mean (SD) 50 (12) 58 (12) 0.001 56 (16) 63 (16) 0.019
Female gender, n (%) 66 (72) 32 (64) 0.34 40 (64) 47 (65) 0.83
Symptom duration <
12 weeks, n (%)
31 (36) 12 (27) 0.31 25 (42) 28 (44) 0.82
66-SJC, median (IQR) 5 (3–10) 6 (3–8) 0.73 8 (4–15) 8 (4–14) 0.96
68-TJC, median (IQR) 11 (6–16) 8 (4–16) 0.06 16 (11–25) 14 (10–21) 0.34
ESR, median (IQR) 29 (16–41) 30 (14–44) 0.60 19 (9–41) 31 (11–52) 0.19
DAS44, median (IQR) 2.9 (2.5–3.5) 2.7 (2.4–3.1) 0.21 3.3 (2.7–4.0) 3.2 (2.6–3.8) 0.66
RF-positive, n (%) 81 (88) 40 (80) 0.20 20 (32) 18 (25) 0.39
Table depicting baseline characteristics of all patients included in the present study, stratified for ACPA status. Missings were as follows: ACPA (2), TJC (9), SJC (8),
ESR (1). RA rheumatoid arthritis, SD standard deviation, SJC swollen joint count, TJC tender joint count, IQR interquartile range, ESR erythrocyte sedimentation rate,
ACPA anticitrullinated protein antibody, RF rheumatoid factor
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multivariable models corrected for baseline differences
as well as for a propensity score were performed in
order to reduce bias caused by confounding by indication.
Altogether, the issue of non-comparability might not be
completely prevented in this way. However, although there
may still be unmeasured confounding, there are also many
important similarities between the two groups. These in-
clude similarities in patient characteristics, inclusion
period, center, and team of treating rheumatologists. This
suggests that the differences observed could be largely at-
tributed to the most important difference between the
groups, namely the treatment strategy that was applied.
Fig. 3 Kaplan-Meier curve depicting the occurrence of late flares by
treatment strategy. Kaplan-Meier curve depicting the occurrence of
late flares by treatment strategy in patients who achieved DMARD-free
remission (n = 90) in the whole group (a) and stratified by ACPA-status
(b, c). DMARD, disease-modifying antirheumatic drug; IT, intensive
treatment; RC, routine care
Fig. 4 Kaplan-Meier curves depicting the percentage of patients
achieving DMARD-free sustained remission by treatment strategy.
Kaplan-Meier curves depicting the achievement of DMARD-free
sustained remission by treatment strategy in all included patients (a)
and stratified by ACPA-status (b, c). DMARD, disease-modifying
antirheumatic drug; HR, hazard ratio; ACPA, anticitrullinated protein
antibodies; RF, rheumatoid factor; IT, intensive treatment; RC,
routine care
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The outcome DMARD-free sustained remission is in-
frequently studied. A previous study from our center
evaluated the difference in DMARD-free remission during
5 years of follow-up in patients with DAS-driven versus
non-DAS-driven therapy [22]. Here, the DAS-driven
group was derived from the BeSt-trial [21]. Because of
stringent inclusion criteria, a rather severe set of RA
patients was included in the trial. As shown by the many
differences in baseline characteristics between both treat-
ment groups [22], non-comparability was a larger issue in
this previous study than in the present investigation.
Despite some methodological limitations, data from this
previous study suggested that ACPA-positive patients had
a greater advantage of DAS-driven therapy [22]. Also, in
our data, ACPA-positive patients achieved DMARD-free
remission more often in the intensive therapy group.
However, after considering the late flares, there was no
significant difference in the DMARD-free remission that
was sustained over time. It is possible that the remaining
difference would have reached statistical significance if the
sample size would have been larger. In contrast, late flares
occurred more often in ACPA-positive patients after
having achieved DMARD-free remission. Consequently, it
is also possible that after a longer follow-up, the rate of
late flares would increase especially in the ACPA-positive
group, diminishing the difference between the intensive
treatment group and routine care in ACPA-positive RA.
Hence, the present data do not allow to conclude that
ACPA-positive RA patients benefit from an intensive
treatment strategy with regard to achieving and sustaining
DMARD-free remission.
Although the long follow-up duration is advantageous
and allowed to study the occurrence of late flares, some
late flares occurred several years after DMARD cessa-
tion. Possibly, the currently observed percentage of
patients achieving late flares is underestimated. In
addition, some late flares may have been missed as
patients in sustained remission can be referred to the
GP with instructions to return if symptoms reoccur.
Despite these instructions and the fact that early access
for RA patients is promoted in several ways, including
the presence of screening clinics [23], we cannot exclude
that some patients were not referred back to our out-
patient clinic in case of recurring symptoms. However,
we do not expect that these issues, if present, depend on
treatment strategy or ACPA status. Similarly, the amount
of patients achieving DMARD-free sustained remission
could be either an underestimation (as more patients
may achieve this after longer follow-up) or an over-
estimation (as patients already having achieved this
outcome could experience a recurrence of clinical
synovitis). However, as follow-up duration was similar
in both treatment arms, we do not expect this would
change the results.
Differences in treatment strategy between the two
groups were not only the difference in treatment target
(DAS < 1.6 instead of 2.4), but also the initial high dose
of prednisone (60 mg/day), and the possibility to switch
to biologicals after 4 months. In regular care, prednisone
was occasionally started next to MTX, but not in a high
dose and biologics were only allowed after failure of > 2
cDMARDS, which (if necessary) generally took place at a
longer disease duration. In contrast to the patients treated
in the trial, treatment changes in the regular care group
were also made at non-protocolized visits and a larger
variety of DMARDs were possible. This hampered a de-
tailed registration of all DMARDs used in the regular care
group. Additionally, it is possible that in routine care,
rheumatologists were more reluctant to taper and stop
DMARDs. However, despite all the differences in treat-
ment strategy between the groups, no important differ-
ences in DMARD-free sustained remission were observed.
The IMPROVED study had a duration of 5 years;
thereafter, patients were treated according to the best
insights of the treating rheumatologist. Thus, after 5 years
of treatment, the strategies became similar between both
groups. This may have resulted in a reduction of initial
contrasts between the groups [24].
The percentage of patients achieving DMARD-free sus-
tained remission was relatively high, but similar to previ-
ous studies on this outcome [13]. Local treatment
guidelines comprise tapering and stopping of DMARDs
also in regular care [13]. This may differ from routine care
elsewhere, especially since EULAR guidelines are cautious
with regard to tapering and subsequent stopping of
DMARDs [2, 16]. Now, several studies have revealed that
DMARD-free remission is an achievable outcome; more
research on tapering and stopping DMARDs is warranted.
Conclusions
In conclusion, the present data showed no benefit from
an intensive treatment regimen compared to routine
care for the long-term outcome DMARD-free sustained
remission in RA. Validation in a randomized setting is
required. Based on the present results, an eventual bene-
fit of an intensive treatment regimen is most expected in
ACPA-positive RA. Because of the occurrence of late
flares particularly in this group, a possible future trial on
this proxy of cure of RA should have a follow-up
duration of ≥ 10 years to come to definite conclusions.
Additional file
Additional file 1: Supplementary methods. Figure S1. DAS44 over time.
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